Table 1.
Inclusion and Exclusion Criteria for the First Round of Literature Evaluation
| Item | Inclusion | Exclusion |
|---|---|---|
| PICO strategy | ||
| Patient population | Japanese patients aged ≥50 years with choroidal neovascularization who meet Japanese wAMD diagnostic criteria29 | Patients with central serous chorioretinopathy, lesions from myopia, and other ocular diseases causing vision impairment, including inflammatory and degenerative diseases |
| Intervention/comparator | Any approved, widely-used, or guideline-recommended interventional therapy in Japana,19 | Studies not reporting any of the listed interventions/comparators of interest |
| Outcomes | Reporting of VA, central retinal thickness, and/or number of injections at 12 months | Studies not reporting outcomes of interest |
| Other criteria | ||
| Article type | RCT, observational study, case series, conference proceeding, current wAMD diagnosis/treatment guidelines | Non-systematically conducted reviews or editorials |
| Sample size | ≥10 Japanese patients with a diagnosis of wAMD | <10 patients |
| Geographic setting | Japan | Any other country |
Notes: aIncludes anti-VEGF alone, anti-VEGF plus photodynamic therapy, photodynamic therapy alone, and other approved treatments.
Abbreviations: PICO, Population, Intervention, Comparison, and Outcome; RCT, randomized controlled trial; VA, visual acuity; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.